Introduction {#sec1}
============

Systemic scleroderma (SSc) is an autoimmune connective tissue disease (CTD) in which microvascular injury plays an important role. Vascular damage is accompanied by activation of the immune system and fibroblasts, which results in autoantibodies production, inflammation and excessive collagen deposition in the skin and internal organs, however the pathogenesis of SSc is still not completely understood. Endothelial cells (ECs) damage is thought to be the very early stage of pathologic processes involved in the development of SSc. Several mechanisms are suggested to be responsible, including defective nitric oxide production, overexpression of VEGF~165~b and increased oxidative stress with overproduction of reactive oxygen species. Furthermore, in SSc decreased amounts of circulating EC progenitor cells were found in peripheral blood, which may be associated with impaired regeneration of endothelium. Several immunological mechanisms have also been postulated, including cytotoxic T lymphocytes activity, ECs apoptosis induced by neutrophils, activation of the classical complement pathway, and last but not least anti-endothelial cell antibodies (AECA) activity \[[@cit0001], [@cit0002]\].

AECA activity are a heterogeneous group of autoantibodies that recognize ECs proteins and particles present on the ECs surface. AECA activity have been described in a number of autoimmune diseases and other conditions \[[@cit0003]\]. Data concerning prevalence of AECA in SSc patients present highly variable results (22--86%), which probably results from diversity of study populations and detection techniques \[[@cit0004]\].

Many pathologic mechanisms of AECA in SSc are considered, including EC activation, induction of coagulation, AECA-induced cytotoxicity and apoptosis of ECs, as well as activation of fibroblasts \[[@cit0004]\]. Still there are concerns whether AECA are just an epiphenomenon of vascular injury without pathogenicity or they underlie SSc-related microangiopathy. Literature data concerning associations of AECA and clinical features of SSc are quite poor. AECA activity were reported to be more common in patients with digital ulcers and gangrene \[[@cit0005]--[@cit0007]\], nailfold capillaroscopic changes \[[@cit0005], [@cit0006]\] and pulmonary hypertension (PAH) \[[@cit0006], [@cit0007]\]. Until now, there have been no studies correlating AECA positivity with activity and duration of the disease.

Aim {#sec2}
===

The aim of the study was to evaluate associations between the presence of AECA in sera of patients with SSc and internal organs involvement as well as disease activity.

Material and methods {#sec3}
====================

Study population {#sec3.1}
----------------

The study comprised 58 consecutive SSc patients (mean age: 56.57 years, range: 25--78 years) hospitalized in the Department of Dermatology, Venerology and Pediatric Dermatology of Lublin between January 2013 and December 2014. We included all patients, who fulfilled the American Rheumatism Association diagnostic criteria for SSc \[[@cit0008]\]. Exclusion criteria included: concomitant infections, neoplasms, cardiovascular and pulmonary diseases not associated with SSc as well as cigarette smoking. Ethical approval was obtained from the Bioethics Committee of Medical University of Lublin and each patient signed informed consent before participating in the study.

Study population was divided into two groups according to the disease subtype \[[@cit0009]\]: limited cutaneous SSc -- lcSSc (*n* = 50) and diffuse cutaneous SSc -- dcSSc (*n* = 8). Furthermore, based on disease duration from the first non-Raynaud symptom, we divided SSc patients into an early (\< 5 years for lcSSc and \< 3 years for dcSSc) and late (\> 5 years for lcSSc and \> 3 years for dcSSc) stage of SSc (*n* = 15 and *n* = 43, respectively) \[[@cit0010]\].

Clinical assessment {#sec3.2}
-------------------

Each patient was carefully examined for the presence of digital scars or ulcers. Modified Rodnan Skin Score was calculated for all studied subjects to determine the severity of skin involvement \[[@cit0011], [@cit0012]\]. Routine laboratory and imaging diagnostic tests were performed to determine disease activity and internal organ involvement. Among laboratory tests we selected serum levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), complement components 3 and 4 (C3, C4) for further analysis.

Lung involvement was evaluated by high resolution computed tomography (HRCT), spirometry and diffusing lung capacity for carbon monoxide (DLCO). In spirometry, performed by BodyScreen II (Jaeger), forced vital capacity (FVC) and total lung capacity (TLC) were analyzed. According to the American Thoracic Society, TLC ≥ 80% and FVC ≥ 75% of predicted values were considered normal. TLC \< 80% and FVC \< 75% were interpreted as restriction \[[@cit0013]\]. Diffusing lung capacity for carbon monoxide was performed by Lung Test 1000 spirometer (MES Ltd.). According to the European Respiratory Society, results \< 80% of predicted values were considered as decreased diffusing lung capacity \[[@cit0014]\].

Heart function was evaluated by echocardiography (B-mode and color Doppler imagining) and standard, 12-lead electrocardiography (ECG). Esophageal disorders were examined by upper gastrointestinal X-ray series. X-ray images of hands were performed to determine the presence of acroosteolysis and calcinosis.

In order to assess cutaneous microcirculation, nailfold capillaroscopy (NC) was performed in each subject. We used a video-capillaroscope VideoCap 3.0 Derma (DS Medica). According to Cutolo *et al.*, obtained capillaroscopic images were divided into early, active and late patterns \[[@cit0015]\].

To determine activity of SSc, we used 10-points activity index for SSc developed by the European Scleroderma Study Group (EScSG). Results ≥ 3 points were indicative for active disease \[[@cit0016]\].

Anti-endothelial cell antibodies activity identification {#sec3.3}
--------------------------------------------------------

To measure the presence of AECA, clotted blood samples were collected from all SSc patients in the amount of 5 ml. Hyperlipidemic or hemolyzed samples were not analyzed. An indirect immunofluorescence procedure with human umbilical vein endothelial cells (HUVEC) and monkey skeletal muscles as substrates was performed. We used TITERPLANE technique elaborated by EUROIMMUN.

Human umbilical vein endothelial cells cultures and frozen monkey skeletal muscles were incubated for 30 min with diluted 1 : 100 sera from SSc patients on biochip platforms. After incubation, platforms were rinsed with PBS-Tween wash buffer. During the second stage of incubation AECA antibodies bound to the substrate were identified by goat anti-human IgG antibodies marked with fluorescein (30 min in room temperature), and the rinsed again with PBS-Tween wash buffer. Microscopic evaluation was performed by fluorescent microscope Nikon TS100. Positive reaction was interpreted qualitatively and on ECs was characterized by cytoplasmic, granular, yellowish-green fluorescence concentrated around nucleus ([Figure 1](#f0001){ref-type="fig"}).

![Positive AECA reaction manifesting with cytoplasmic, granular, yellowish-green fluorescence concentrated around nuclei](PDIA-35-32551-g001){#f0001}

Statistical analysis {#sec3.4}
--------------------

Statistical analysis was performed with the use of Statistica 10.0 PL package. Data were analyzed for normal distribution using the Shapiro-Wilk test. For normally distributed data, parametric *t*-Student test was used, while equality of variances was checked by exact Fisher's test. For non-parametric data U Mann-Whitney test was performed. *P*-value \< 0.05 was considered statistically significant.

Results {#sec4}
=======

AECA activity antibodies were present in 21 patients with SSc (36.21%). Majority of dcSSc patients were AECA-positive (75%, *n* = 6), while prevalence of AECA positive individuals among lcSSc patients was 30% (*n* = 15). Statistical analysis (Fisher's exact test) revealed a significant association between positive AECA and a subtype of SSc (*p* = 0.021; [Table 1](#t0001){ref-type="table"}). We found no association between disease duration, disease activity and AECA presence (*p* = 1.000 and *p* = 0.191, respectively).

###### 

Presence of AECA antibodies depending on the SSc subtype, disease duration and disease activity (statistically significant values in bold)

  Parameter          Total      AECA absent   AECA present   *P-*value     
  ------------------ ---------- ------------- -------------- ------------- -----------
  Disease subtype    lcSSc      50            35 (70.00%)    15 (30.00%)   **0.021**
  dcSSc              8          2 (25.00%)    6 (75.00%)                   
  Disease duration   Early      15            10 (66.67%)    5 (33.33%)    1.000
  Late               43         27 (62.79%)   16 (37.21%)                  
  Disease activity   Inactive   45            31 (68.89%)    14 (31.11%)   0.191

Prevalence of clinical signs, visceral involvement and abnormal clinical test results in patients with SSc are shown in [Table 2](#t0002){ref-type="table"}. In the studied group, we found a significant association between positive AECA and the presence of active digital ulcers or digital scars. AECA were more common in patients with digital scars and active digital ulcers when compared to those without trophic lesions (*p* = 0.001). Furthermore, AECA were significantly more frequent in patients with calcinosis and acroosteolysis ([Table 2](#t0002){ref-type="table"}).

###### 

Organ involvement and laboratory test results in patients with SSc in relation to AECA presence (statistically significant values in bold)

  Clinical sign/test result             Present (+)/absent (--)   Total         AECA (--)     AECA (+)      *P*-value
  ------------------------------------- ------------------------- ------------- ------------- ------------- -----------------------------------
  Digital ulcers/ scars                 \+                        39            19 (48.72%)   20 (51.28%)   **0.001**
  --                                    19                        18 (94.74%)   1 (5.26%)                   
  Calcinosis                            \+                        6             1 (16.67%)    5 (83.33%)    **0.02**
  --                                    52                        36 (69.23%)   16 (30.77%)                 
  Acroosteolysis                        \+                        22            10 (45.45%)   12 (54.55%)   **0.047**
  --                                    35                        26 (74.29%)   19 (25.71%)                 
  Modified Rodnan skin score            ≥ 14                      6             2 (33.33%)    4 (66.67%)    0.176
  \< 14                                 52                        35 (67.31%)   17 (32.69%)                 
  Lung fibrosis in HRCT                 \+                        44            25 (56.82%)   19 (43.18%)   0.062
  --                                    14                        12 (85.71%)   2 (14.29%)                  
  Restriction on spirometry             \+                        17            13 (76.47%)   4 (23.53%)    0.129
  --                                    33                        17 (51.52%)   16 (48.48%)                 
  ECG changes                           \+                        18            11 (61.11%)   7 (38.89%)    0.777
  --                                    40                        26 (65.00%)   14 (35.00%)                 
  ECHO                                  \+                        35            22 (62.86%)   13 (37.14%)   1.000
  --                                    23                        15 (65.22%)   8 (34.78%)                  
  Esophageal changes                    \+                        43            27 (62.79%)   16 (37.21%)   1.000
  --                                    15                        10 (66.67%)   5 (33.33%)                  
  Capillaroscopic pattern (by Cutolo)   Early                     17            12 (70.59%)   5 (29.41%)    0.625[^C^](#tf2-1){ref-type="fn"}
  Active                                14                        8 (57.14%)    6 (42.86%)                  
  Late                                  23                        13 (56.52%)   10 (43.48%)                 
  DLCO                                  Decreased \< 80%          24            18 (75.00%)   6 (25.00%)    0.162
  Normal ≥ 80%                          30                        16 (53.33%)   14 (46.67%)                 
  FVC                                   Decreased \< 75%          3             2 (66.67%)    1 (33.33%)    1.000
  Normal ≥ 75%                          47                        28 (59.57%)   19 (40.43%)                 
  TLC                                   Decreased \< 80%          17            13 (76.47%)   4 (23.53%)    0.235
  Normal ≥ 80%                          38                        22 (57.89%)   16 (42.11%)                 
  ESR                                   Elevated                  38            26 (68.42%)   12 (31.58%)   0.392
  Normal                                20                        11 (55.00%)   9 (45.00%)                  
  CRP                                   Elevated                  19            12 (63.16%)   7 (36.84%)    1.000
  Normal                                39                        25 (64.10%)   14 (35.90%)                 
  C3                                    Decreased                 8             5 (62.50%)    3 (37.50%)    1.000
  Normal                                50                        32 (64.00%)   18 (36.00%)                 
  C4                                    Decreased                 3             2 (66.67%)    1 (33.33%)    1.000
  Normal                                55                        35 (63.64%)   20 (36.36%)                 

Significant differences for α = 0.05 (two-tailed test).

χ^2^ test.

HRCT -- high resolution computed tomography, ECG -- electrocardiography, ECHO -- echocardiography, DLCO -- diffusing capacity of the lung for carbon monoxide, FVC -- forced vital capacity, TLC -- total lung capacity, ESR -- erythrocyte sedimentation rate, CRP -- C-reactive protein, C3 -- complement component 3, C4 -- complement component 4.

No associations were found between AECA presence and modified Rodnan Skin Score, ECG changes, echocardiographic alterations, esophageal dysfunction and nailfold capillaroscopic pattern. Moreover, alterations in spirometry, DLCO, CRP and ESR elevation, complement components C3 and C4 decrease were not more common in patients positive for AECA.

Discussion {#sec5}
==========

Nearly 45 years have passed since AECA were first detected by Lindquist and Osterland \[[@cit0017]\]. The presence of AECA was later described in a number of autoimmune disorders including SSc, vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis as well as other conditions, such as diabetes mellitus, atherosclerosis, in heart transplant recipients with vascular rejection \[[@cit0018]\], and, lately in graft versus host disease \[[@cit0019]\]. Moreover, in recent years there has been a wide interest in the role of AECA in the development of pulmonary arterial hypertension (PAH), both idiopathic and associated with CTDs \[[@cit0020]\].

Pathological mechanisms of AECA are not fully understood yet. However, data exist that AECA induce activation of ECs which results in inflammatory cytokines production and increase of adhesion molecules expression. Furthermore, AECA are thought to be responsible for antibody-dependent cellular cytotoxicity (ADCC) against ECs, complement system activation and probably to have procoagulatory effects \[[@cit0004]\]. It was proved that AECA induce apoptosis of EC progenitor cells in bone marrow in SSc patients, which results in disturbances in endothelial regeneration and healing of vascular lesions \[[@cit0021]\].

Many different methods are used to detect AECA; however, to date, there has been no standardization for AECA identification \[[@cit0022]\]. Recent studies have focused on identification of AECA target proteins; however, they have yielded divergent results. Garcia de la Pena-Lefebvre *et al.* concluded that AECA from patients with dcSSc bind to ECs' topoisomerase-1 independently of the presence of anti-Scl-70 antibodies in the patient serum, and this is a distinguishing feature between lcSSc and dcSSc patients \[[@cit0023]\]. In the next paper the same authors identified ubiquitous CENP-B as the main target of anti-endothelial cell antibodies in patients with lcSSc \[[@cit0024]\]. In one of the recent studies, Dib *et al.* used two-dimensional electrophoresis and immunoblotting with protein extracts of HUVECs and mass spectrometry for detection of AECA targets in SSc and PAH patients, and identified them as lamin A/C and tubulin β chain. They found the biggest amount of protein spots in patients with SSc and PAH (*n* = 110), less in SSC patients without PAH (*n* = 82) and the lowest amount in idiopathic PAH patients (*n* = 37). However, the functional significance of these findings remains unclear \[[@cit0020]\].

Lately, interesting research has been published in which one of AECA targets was identified as ICAM-1. The authors have proved that anti-ICAM AECA stimulate pro-inflammatory activation of human ECs, which manifests as an increase in reactive oxygen species generation and VCAM-1 expression \[[@cit0018]\].

In the present study we used II Fas a detection method for AECA, with HUVEC and skeletal muscle of monkey as substrates. As shown in laboratory tests, skeletal muscle provide a wider spectrum of antigens, which increases the sensitivity of the method and in SSc patients, the highest prevalence of AECA was obtained with immunoblot with HUVEC as a substrate \[[@cit0025]\]. In our study the prevalence of AECA among SSc patients was 36.21%, which is consistent with previous reports.

Our results showed a significant association between the presence of AECA and subset of the disease. AECA were more common among patients with dcSSc than lcSSc. Literature data concerning the association between SSc subset and AECA are somewhat conflicting. Pignone *et al.* and Salozhin *et al.* did not find such association \[[@cit0006], [@cit0026]\], whereas Salojin *et al.* observed AECA in 16 of 36 (44%) patients with lSSc, and 26 of 31 (83%) patients with dSSc \[[@cit0005]\].

Furthermore, we have found, consistently with previous reports, that AECA are significantly more common in patients with digital ulcers or digital gangrene \[[@cit0005]--[@cit0007], [@cit0026]\]. In one of the studies, AECA positive patients with digital infarcts and PAH had significantly higher levels of AECA than other AECA-positive patients \[[@cit0007]\].

Wusirika *et al.* reported a positive relationship between lung fibrosis in SSc patients evaluated by HRCT as well as PAH and the presence of AECA measured by IIF. In Western blot analysis they found antibodies binding to proteins in extracts of human EC in all patients in whom there was evidence of pulmonary disease \[[@cit0027]\]. In a study by Lewandowska *et al.*, AECA were highly prevalent in a subgroup of patients suffering from interstitial pulmonary fibrosis (7 of 15 AECA positive patients had lung fibrosis) \[[@cit0028]\].

In SSc it is postulated that cytokines produced by activated ECs interact with tissue fibroblasts, increasing their proliferation and differentiation as well as inhibiting their apoptosis, which results in collagen overproduction and fibrosis \[[@cit0004]\]. In the presented study we also found a tendency towards positive association between AECA and lung fibrosis evaluated by HRCT. Reversely, Pignone *et al.* found no association between HRCT lesions and AECA among 50 patients with SSc. Similar observations come from the report of Salozhin *et al.* \[[@cit0006], [@cit0029]\].

Considering lung function tests, Pignone *et al.* reported a higher prevalence of decreased DLCO values among patients with dcSSc and AECA \[[@cit0006]\]; however, our results did not show such association. There was also no association with decreased FVC and TLC and we found no data in literature concerning such relationship.

According to the microvascular abnormalities observed by nailfold capillaroscopy (NC), our study did not confirm the association between the presence of AECA and the SSc capillaroscopic patterns (early, active or late) ([Table 2](#t0002){ref-type="table"}). Moreover, we did not find any statistically significant differences in AECA positivity depending on the presence and severity of particular changes in capillary morphology typical for SSc microangiopathy, i.e. megacapillaries, microhemorrhages, neoangiogenesis, capillary loss and avascular areas (data not shown). This is somewhat opposite to previous studies. Pignone *et al.* as well as Salozhin *et al.* found an association between NC abnormalities and positive AECA in SSc patients \[[@cit0006], [@cit0026]\]. Salojin *et al.* reported a relationship between positive AECA and vessels tortuosity of grade 3 \[[@cit0005]\]. Riccieri *et al.* found that AECA-positive patients had more severe NC changes, in particular late capillaroscopic pattern \[[@cit0029]\].

Pignone *et al.* as well as Salozhin *et al.* found no relationship between skin involvement measured by Rodnan skin score and positive AECA \[[@cit0006], [@cit0026]\], which is consistent with our results. Reversely, in a study by Riccieri *et al.*, patients with higher AECA serum levels showed significantly greater results of modified skin score (≥ 15, *p* \< 0.04) \[[@cit0029]\]. In our study, the lack of association between AECA presence and modified Rodnan skin score may be a result of a limited sample size for dcSSc.

We were not able to confirm any association between AECA and heart involvement. In the current literature there are only two studies evaluating cardiac disease in SSc in relation to AECA and in both of them, cardiac dysfunction assessed by echocardiography and ECG was not more common in AECA-positive patients \[6, [@cit0026]\]. Moreover, we found a positive association between AECA and acroosteolysis and no relationship between AECA and esophageal involvement, which is consistent with the study by Salozhin *et al.* \[[@cit0026]\]. Interestingly, we found a significant association between calcinosis and AECA presence in contrast to other reports \[[@cit0026]\].

Finally, in some systemic inflammatory conditions, i.e. SLE and systemic vasculitis AECA titers were found to correlate well with disease activity \[[@cit0030], [@cit0031]\]. There are no data in the literature concerning the relationship between SSc activity and the presence of AECA. We found no associations between CRP, ESR, C3 and C4 serum levels and AECA, and our results did not confirm the relationship between overall activity of SSc measured by EscSG disease activity index and AECA. We also did not find any association between disease duration and AECA and there are no literature data on that topic.

The limitations of the present study include its single center character, small sample size and a limited number of patients with dcSSc enrolled. Furthermore, patients were recruited consecutively and only female patients were included in the study.

Conclusions {#sec6}
===========

Anti-endothelial cell antibodies do not correlate with the activity of SSc. Digital ulcers, calcinosis and acroosteolysis are more common among AECA-positive patients suggesting that the presence of AECA might be an indicator of vascular complication development in SSc, although they are not associated with NC patterns. Positive AECA among patients with lung fibrosis indicate their possible role in the development of lung disease. Further prospective studies including a greater number of patients with a unified and standardized detection method are required to fully elucidate the clinical significance of AECA as well as their prognostic value in SSc.
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